drugset / Trial / NCT00415311
A Multicenter Study Evaluating the Safety and Tolerability of Intravenous rhMBL in Liver Transplant Recipients.
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, open-label, randomized, Phase 1B study evaluating liver transplant recipients receiving rhMBL (2 cohorts) or without rhMBL (1 cohort).
Timeline
- Start
- 2006-12
- Primary completion
- 2009-06
- Completion
- 2009-12
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision to terminate the study”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | rhMBL | Protein / enzyme biologic | 0.5 mg/kg | Intravenous |
| Subject | rhMBL | Protein / enzyme biologic | 1 mg/kg | Intravenous |
Indications
No indication recorded.